-

TRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS: TCDA).

On July 15, 2020, the Company disclosed that it received a notification from the U.S. Food and Drug Administration (FDA) regarding its ongoing review of the Company’s New Drug Application (NDA) for its drug candidate, veverimer (TRC101) wherein “the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.” Then, on October 29, 2020, the Company disclosed that the FDA had informed it that the FDA was “unlikely to rely solely on serum bicarbonate data for determination of efficacy” and would “require evidence of veverimer’s effect on CKD progression from a near-term interim analysis of the VALOR-CKD trial for approval under the Accelerated Approval Program.” Finally, on February 25, 2021, the Company disclosed that the FDA had denied the appeal of its NDA denial.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws. Recently, the court presiding over that case denied the Company’s motion to dismiss in part, allowing the case to move forward.

KSF’s investigation is focusing on whether Tricida’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Tricida shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-tcda/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:TCDA

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

CORRECTING and REPLACING Klarna Group plc Securities Class Action Result of Understated Risks and Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Headline of release should read: Klarna Group plc Securities Class Action Result of Understated Risks and Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC (instead of Klarna Group plc Securities Fraud Class Action Result of Understated Risks and Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC). The updated release reads: KLARNA GROUP PLC SECURITIES CLASS ACTION RESULT OF UNDERS...

ASP Isotopes Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ASP Isotopes, Inc. - ASPI

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ASP Isotopes, Inc. (NasdaqCM: ASPI). ASP Isotopes (“ASP” or the “Company”) is a development stage advanced materials company focused on the production, enrichment, and sale of isotopes. In November 2024, market research firm Fuzzy Panda Research released a report acc...

F5, Inc. Securities Fraud Class Action Result of Data Breach and Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until February 17, 2026 to file lead plaintiff applications in a securities class action lawsuit against F5, Inc. (NasdaqGS: FFIV), if they purchased or otherwise acquired the Company’s securities between October 28, 2024, and October 27, 2025, inclusive (the “Class Period”). This act...
Back to Newsroom